涉嫌严重违纪违法，李欣被查

Core Viewpoint - The investigation of Li Xin, former assistant general manager of China National Pharmaceutical Group, highlights ongoing anti-corruption efforts within the pharmaceutical industry in China [1][4]. Group 1: Investigation Details - Li Xin is under investigation for serious violations of discipline and law, currently being reviewed by the Central Commission for Discipline Inspection and the Shandong Provincial Supervisory Committee [1]. - Li Xin has a long career in the pharmaceutical industry, having held various managerial positions since 1997, including roles at Beijing Yongzheng Pharmaceutical and China National Pharmaceutical [4]. Group 2: Company Background - China National Pharmaceutical Group, a publicly listed company, is controlled by the General Technology Group and serves as its sole platform for pharmaceutical and medical device production and operation [4]. - As of November 21, the stock price of China National Pharmaceutical was 10.87 yuan per share, with a total market capitalization of 16.3 billion yuan [4]. Group 3: Industry Context - The anti-corruption campaign in the pharmaceutical sector has intensified, with multiple individuals from China National Pharmaceutical facing investigations this year, including Wang Zhiguang, a deputy general manager [4]. - The Ministry of Health and 14 other ministries issued a notice in June to address corruption and misconduct in the pharmaceutical sales and medical services sectors, aiming for ongoing governance of unethical practices [5].